Showing results (11-20 of 65) with videos related to
Sort By:
Pageof 7
Journal of Oncology Practice|September 12, 2019
When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?Kim DeLeonardis, Lauren Hogan, Stephen A Cannistra, et al.Respiratory Medicine Case Reports|April 23, 2019
Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literatureCamille R Petri, Rushad Patell, Felipe Batalini, et al.The Oncologist|September 24, 2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR MutationsKartik Sehgal, Deepa Rangachari, Paul A VanderLaan, et al.Cells|December 24, 2021
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical ScenariosIkei S Kobayashi, Hollis Viray, Deepa Rangachari, et al.Journal for Immunotherapy of Cancer|June 26, 2020
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Kartik Sehgal, Andreas Varkaris, Hollis Viray, et al.Blood Cells, Molecules & Diseases|October 4, 2024
Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directionsCharlotte S Walmsley, Zachary Schoepflin, Charlotte De Brabandt, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 21, 2025
A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non-Small Cell Lung CarcinomasCristiana M Pineda, Zoe Guan, Hyunwoo Kwon, et al.Clinical Lung Cancer|April 6, 2017
Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center AnalysisMarcello DiStasio, Yigu Chen, Deepa Rangachari, et al.Journal of the American Society of Cytopathology|May 2, 2018
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?Vanda F Torous, Deepa Rangachari, Benjamin P Gallant, et al.Cancer Treatment and Research Communications|September 13, 2018
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitisMeghan Shea, Deepa Rangachari, Robert W Hallowell, et al.Pageof 7